Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 30, 2013

CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

 

Delaware

 

001-33057

 

76-0837053

(State or other jurisdiction

of incorporation)

 

(Commission File

Number)

 

(I.R.S. Employer

Identification No.)

 

355 Alhambra Circle

Suite 1500

Coral Gables, Florida

 

33134

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code:   (305) 529-2522

        Not Applicable        

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders

On May 30, 2013, Catalyst Pharmaceutical Partners, Inc. (the “Company”) held its Annual Meeting of Stockholders at the Hyatt Regency Coral Gables, 50 Alhambra Plaza, Coral Gables, Florida. The final voting results on the matters considered at the meeting are as follows:

 

1. Election of Directors:

 

Name

   Votes For    Votes Withheld    Broker Non-Votes

Patrick J. McEnany

   17,855,170    263,730    15,151,838

Philip H. Coelho

   17,822,170    296,730    15,151,838

Hubert E. Huckel

   17,800,055    318,845    15,151,838

Charles B. O’Keeffe

   17,852,216    266,684    15,151,838

David S. Tierney

   17,855,770    263,130    15,151,838

 

2. Approval, on an advisory basis, of the compensation of the Company’s named executive officers:

 

Votes For

 

Votes Against

 

Votes Abstained

 

Broker Non-Votes

17,604,563

  420,034   94,303   15,151,838

 

3. Selection, on an advisory basis, of the frequency of “say-on-pay” votes:

 

One Year

 

Two Years

 

Three Years

 

Abstain

 

Broker Non-Votes

11,366,380

  281,389   6,178,514   292,617   15,151,838

 

4. Ratification of the selection of Grant Thornton, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013:

 

Votes For

 

Votes Against

 

Votes Abstained

33,043,182

  153,011   74,545


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Catalyst Pharmaceutical Partners, Inc.
By:   /s/ Alicia Grande

Alicia Grande

Vice President, Treasurer and Chief

Financial Officer

 

 

Dated: June 3, 2013